Profile data is unavailable for this security.
About the company
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
- Revenue in SEK (TTM)737.16m
- Net income in SEK150.21m
- Incorporated1994
- Employees228.00
- LocationCellaVision ABMobilvagen 12LUND 223 62SwedenSWE
- Phone+46 464601600
- Fax+46 462864470
- Websitehttps://www.cellavision.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioPorto A/S | 52.61m | -77.78m | 1.18bn | 33.00 | -- | 7.24 | -- | 22.43 | -0.1397 | -0.1397 | 0.0941 | 0.244 | 0.2777 | 3.23 | 9.02 | 1,091,290.00 | -41.06 | -71.10 | -51.28 | -96.55 | 71.13 | 63.38 | -147.84 | -239.22 | 5.16 | -- | 0.0517 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Sedana Medical AB (publ) | 174.14m | -57.24m | 1.29bn | 78.00 | -- | 1.36 | -- | 7.40 | -0.5763 | -0.5763 | 1.75 | 9.56 | 0.1697 | 1.16 | 10.14 | 2,204,317.00 | -5.58 | -5.77 | -5.84 | -6.08 | 70.60 | 64.06 | -32.87 | -36.13 | 6.02 | -30.48 | 0.0076 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| Paxman AB (publ) | 238.86m | 28.64m | 1.38bn | 102.00 | 48.30 | 9.46 | 29.40 | 5.78 | 1.50 | 1.50 | 12.54 | 7.67 | 1.31 | 2.74 | 6.56 | 2,624,791.00 | 15.66 | -5.08 | 20.74 | -7.76 | 70.27 | 69.38 | 11.99 | -5.07 | 1.98 | 12.73 | 0.0838 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
| Nordhealth As | 479.02m | -108.23m | 1.56bn | 355.00 | -- | 3.01 | 92.54 | 3.26 | -1.41 | -1.41 | 6.22 | 11.68 | 0.4329 | -- | 6.73 | 1,233,004.00 | -9.78 | -- | -11.11 | -- | 85.82 | -- | -22.59 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
| Genovis AB | 127.02m | 17.25m | 1.67bn | 37.00 | 96.59 | 8.02 | 57.32 | 13.12 | 0.2635 | 0.2635 | 1.94 | 3.17 | 0.4938 | -- | -- | 3,432,973.00 | 6.71 | 18.56 | 7.21 | 21.45 | 64.41 | 65.51 | 13.58 | 23.88 | -- | 697.00 | 0.2718 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Stille AB | 487.43m | 50.86m | 1.92bn | 151.00 | 33.82 | 2.86 | 25.63 | 3.94 | 6.33 | 6.33 | 60.94 | 74.85 | 0.6978 | 2.10 | 8.49 | 4,598,368.00 | 7.28 | 7.03 | 8.70 | 8.19 | 49.17 | 43.93 | 10.43 | 9.85 | 1.12 | 7.41 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
| Detection Technology Oyj | -1.16tn | -1.16tn | 2.38bn | 464.00 | -- | 2.78 | -- | -- | -- | -- | -- | 5.03 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.39 | -- | 0.00 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| Medistim ASA | 538.07m | 99.96m | 2.44bn | 152.00 | 24.42 | 6.13 | 19.62 | 4.54 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| BICO Group AB | 2.25bn | -786.80m | 2.66bn | 828.00 | -- | 0.9199 | -- | 1.18 | -11.15 | -15.20 | 31.92 | 41.79 | 0.3602 | 2.15 | 4.47 | 2,547,964.00 | -12.62 | -- | -14.44 | -- | 55.70 | -- | -35.03 | -- | 2.23 | -0.5705 | 0.397 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| RaySearch Laboratories AB (publ) | 1.13bn | 151.22m | 5.19bn | 403.00 | 44.23 | 8.70 | 12.37 | 4.60 | 4.41 | 4.41 | 32.91 | 22.41 | 0.5701 | 4.50 | 3.11 | 2,901,244.00 | 7.64 | 1.29 | 11.80 | 1.88 | 90.48 | 90.57 | 13.40 | 2.55 | 1.17 | -- | 0.3937 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| CellaVision AB | 737.16m | 150.21m | 5.80bn | 228.00 | 38.59 | 7.55 | 30.21 | 7.86 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| Surgical Science Sweden AB | 838.25m | 197.72m | 6.18bn | 265.00 | 31.26 | 1.35 | 24.20 | 7.37 | 3.87 | 3.87 | 16.43 | 90.02 | 0.1695 | 1.49 | 7.35 | 3,224,027.00 | 4.00 | 4.49 | 4.26 | 4.78 | 68.51 | 70.06 | 23.59 | 23.75 | 3.46 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Data as of Nov 11 2024. Currency figures normalised to CellaVision AB's reporting currency: Swedish Krona SEK
33.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SEB Investment Management ABas of 31 May 2024 | 2.18m | 9.14% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 1.28m | 5.38% |
| Invesco Advisers, Inc.as of 30 Apr 2024 | 937.36k | 3.93% |
| Fj�rde AP-fondenas of 29 May 2024 | 723.96k | 3.04% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 677.67k | 2.84% |
| AMF Fonder ABas of 31 May 2024 | 555.95k | 2.33% |
| Candriam Belgium SAas of 31 May 2024 | 537.06k | 2.25% |
| Raiffeisen Kapitalanlage-Gesellschaft mbHas of 30 Sep 2024 | 423.50k | 1.78% |
| Nordea Investment Management ABas of 30 Jun 2024 | 348.20k | 1.46% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 30 Sep 2024 | 346.45k | 1.45% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
